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L-Argininea b s t r a c t
Hyperpolarization enhances the intensity of the NMR signals of a molecule, whose in vivo metabolic fate
can be monitored by MRI with higher sensitivity. SABRE is a hyperpolarization technique that could
potentially be used to image nitric oxide (NO) production in vivo. This would be very important, because
NO dysregulation is involved in several pathologies, including cardiovascular ones. The nitric oxide syn-
thase (NOS) pathway leads to NO production via conversion of L-arginine into L-citrulline. NO is a free
radical gas with a short half-life in vivo (5 s), therefore direct NO quantification is challenging. An indi-
rect method – based on quantifying conversion of an L-Arg- to L-Cit-derivative by 1H NMR spectroscopy –
is herein proposed. A small library of pyridyl containing L-Arg derivatives was designed and synthesised.
In vitro tests showed that compounds 4a–j and 11a–c were better or equivalent substrates for the eNOS
enzyme (NO2
 production = 19–46 lM) than native L-Arg (NO2 production = 25 lM). Enzymatic conver-
sion of L-Arg to L-Cit derivatives could be monitored by 1H NMR. The maximum hyperpolarization
achieved by SABRE reached 870-fold NMR signal enhancement, which opens up exciting future perspec-
tives of using these molecules as hyperpolarized MRI tracers in vivo.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Nuclear magnetic resonance (NMR) is the most powerful tech-
nique used for identifying and characterizing organic molecules.1
Unfortunately, NMR is inherently affected by a lack of sensitivity.2
Magnetic resonance imaging (MRI) is a widely used clinical imag-
ing technique that shares the same principles of NMR, and presents
the same inherent problem of low sensitivity, which limits its
application in many fields.3 Recently, several hyperpolarization
techniques have been developed to overcome the sensitivity issue
of NMR and MRI, allowing detection of trace amounts of a certain
compound in a complex mixture,4,5 detection of a metabolite in
cells6 or real-time imaging in small rodents.7 The most used hyper-
polarisation techniques are dynamic nuclear polarization (DNP),8,9spin-exchange optical pumping (SEOP), metastability exchange
optical pumping (MEOP),10 parahydrogen induced polarization
(PHIP)11 and spontaneous amplification by reversible exchange
(SABRE),11–13 which recently emerged as a promising modality
for in vivo pre-clinical and clinical MRI.14,15
SABRE exploits the singlet spin state of parahydrogen (pH2) –
one of the spin states of the H2 molecule – in order to increase
the NMR signal. Compared to other hyperpolarization techniques,
SABRE has the remarkable advantages that the substrate to
hyperpolarize remains structurally unchanged and it is relatively
non-expensive. Polarization transfer occurs through an iridium(I)
complex that acts as a catalyst. Generally the catalytic system con-
tains a carbene group that aids the process (Fig. 1).16,17 SABRE has
been shown to be effective in the hyperpolarisation of various spin
± ½ nuclei such as 1H,18 15N19–22 or 31P.23 Biologically relevant
molecules have been hyperpolarised,24,25 the catalyst can be
deactivated26 and hyperpolarisation in aqueous and biologically
compatible media has also been achieved.27–29
Nitric oxide synthases (NOS) are a family of enzymes that catal-
yse the synthesis of nitric oxide (NO) from L-arginine through an
Fig. 1. In the SABRE process, the iridium catalyst mediates polarization transfer
from para-hydrogen to the pyridyl substrate. This process repeats allowing the
creation of a solution of hyperpolarised pyridyl substrate.
Scheme 1. Reaction catalysed by NOS enzymes leading to NO production.
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producing L-citrulline, a reaction co-product (Scheme 1).30 Three
NOS isoforms are known: neuronal (nNOS, NOS-1), inducible
(iNOS, NOS-2) and endothelial (eNOS, NOS-3).31 nNOS and eNOS
are constitutive isoforms and Ca2+ dependent, while iNOS is Ca2+-
insensitive and activated by pro-inflammatory cytokines in
certain situations of stress or disease as a response of the immune
system.32 NO is a free radical molecule involved in many functions,
such as vascular tone and blood pressure regulation,33 blood flow
in the kidney,34 penile and clitoral erection,35 immune response36
and neuronal transmission.37 It has been reported that abnormal
NO formation or NO dysregulation play an important role in cer-
tain conditions such as type 2 diabetes,38 heart failure,39 haemoly-
tic disorders40 or critical illness myopathy.41 Therefore, detection
of NO production in vivo would be highly beneficial. Direct
in vivo detection of NO is challenging because of its very short bio-
logical half-life (a few seconds). Moreover, current methods for
detecting and quantifying NO in vivo are affected by significant
drawbacks.42 Conversion of L-arginine or L-NOHA to L-citrulline
derivatives could be indirectly but effectively tracked by the shift-
ing of the hyperpolarized NMR signal from the enzymatic substrate
(L-arginine or L-NOHA) to the product L-citrulline. However, pre-
liminary experiments showed that native L-arginine cannot be effi-
ciently hyperpolarised via SABRE because – unlike pyridine and its
derivatives – it is not a sufficiently good ligand for the iridium(I)
catalyst.
Herein we report on the effective hyperpolarization of L-argi-
nine-type pyridyl-amide substrates of endothelial nitric oxide syn-
thase (eNOS). These molecular probes can be used to detect in vitro
the activity of eNOS by 1H NMR spectroscopy and might find future
use as MRI probes in in vivo studies.2. Results and discussion
2.1. Design of L-arginine derivatives as eNOS substrates
It has been previously demonstrated that the guanidine moiety
of eNOS substrates cannot be modified without causing a dramaticloss of efficiency in the enzymatic conversion to urea and conse-
quent release of NO. In fact, small structural modifications of the
L-arginine side chain, such as guanidine methylation or replace-
ment of the d-methylene with oxygen or carbonyl function
afforded substrates with significantly lower affinity or even con-
verted them into potent inhibitors of the NOS enzyme.43–48
On the other hand, Grant et al.47 reported that the a-amino
moiety is involved in the binding through the formation of a hydro-
gen bond in the active pocket of NOS. We therefore decided to
focus on the L-arginine carboxylic function as a plausible site for
the introduction of the iridium(I)-binding pyridine group, by
installing a pyridyl-amide on L-arginine analogues. Diverse pyridyl
amines differently substituted and equipped with a spacer were
selected (structures 2a–i, Scheme 2), since the length of the spacer
and the pyridine substitution was expected to affect the level of
polarization transfer by SABRE.
In addition, considering that L-NOHA activity is similar or higher
than that of L-arginine,46,48 we decided to explore also L-NOHA ana-
logues incorporating a pyridine ring, such as 11a (Scheme 4). Since
it has been shown that neither the carboxylic nor the a-amino
functions of L-NOHA are required for enzymatic recognition – in
fact, some N-substituted alkyl hydroxyguanidines displayed com-
parable activity to that of native L-arginine (i.e. N-butylhydrox-
yguanidine)49,50 – we included in our study also L-NOHA
derivatives lacking the a-amino function (such as 11b, Scheme 4)
or having a protected a-amino group (11c, Scheme 4).2.2. Synthesis of L-arginine derivatives
Compounds 4a–i were synthesised starting from commercially
available Boc-L-Arg(Pbf)-OH 1 (Scheme 2, Eq. 1), that was coupled
with the corresponding amino pyridines 2a–i with HATU as the
coupling agent to afford the protected amides 3a–i in good yields.
Pbf and Boc protecting groups were cleaved from 3a–i in a TFA/
CH2Cl2 95:5 mixture to yield the final free compounds 4a–i. Purifi-
cation of 4a–i was performed on a Sep-Pak C-18 cartridge using
water as the eluent. The TFA counter-ion was exchanged to
hydrochloride by dissolving 4a–i in diluted HCl and freeze-drying
as many times as necessary. In order to obtain 4d and 4i, commer-
cially available 3-(4-pyridyl)alanine 5 and 3-(3-pyridyl)alanine 6
respectively (Scheme 3) were dissolved in methanol and treated
with SOCl2 to afford the methyl ester derivatives 2d and 2i, which
were coupled to 1 as previously described. Compound 4j required
deprotection of the methyl ester from 4i (Scheme 2, Eq. 2), using
LiOH overnight to yield 3j, which was converted into 4j as
described above.
Synthesis of the second generation of compounds, e.g. L-NOHA
analogues 11a–c, is shown in Scheme 4. Compound 11a was pre-
pared by starting from the commercially available amino acid
Boc-Cit-OH 7 which was coupled to 4-picolylamine to afford 8
(Scheme 4, Eq. 1). Compound 11b (Scheme 4, Eq. 2) was prepared
from 5-aminovaleric acid 12, whose acid function was protected as
methyl ester 13, followed by N-Boc function formation 14. The
methyl ester was then hydrolysed to yield 15, which was coupled
to 4-picolylamine to give 16. After acidic N-Boc removal, the N-
substituted urea 17 was prepared using potassium cyanate in
aqueous HCl. Finally, 11c (Scheme 4, Eq. 3) was synthesised from
8 by deprotecting the N-Boc group in acidic conditions and treating
it with acetic anhydride in basic aqueous solution to yield urea 19.
The three urea derivatives 8, 17 and 19 were treated with CH3-
SO2Cl in pyridine at 40 C to afford the N-cyanamides 9, 18 and 20
(Scheme 4), which were purified by flash chromatography, when
possible. These N-cyanamides were poorly stable, to the extent
that 10 was used as a crude, without purification or characterisa-
tion. L-NOHA derivatives 10 and 11b–c were prepared by
Scheme 2. Synthesis of first generation compounds 4a–j. Reagents and conditions: (a) HATU, TEA, CH2Cl2, r.t., 5 h.; (b) TFA/CH2Cl2 95:5, r.t., 2 h.; (c) LiOH, THF/H2O 4:1, r.t.,
overnight.
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yields and purified by reverse phase HPLC. The Boc protecting
group in 10 was cleaved in dioxane with 4 M HCl (quantitative
yield) to afford 11a. 11b–c were obtained as TFA salts after HPLC
purification, then TFA was exchanged to hydrochloride following
the procedure described above.2.3. Synthesis of L-citrulline derivatives
The three L-citrulline derivatives 21a–c (Scheme 5) were syn-
thesised by coupling commercially available Boc-L-Cit-OH 7 and
the corresponding pyridine function, namely 4-picolylamine, 3-
picolylamine or 4-aminopyridine, using HATU to yield 8 (described
above), 22 and 23, respectively, in good yields. The Boc protecting
group was cleaved by reaction with 4 M HCl in dioxane to afford
L-citrulline derivatives 21a–c.Scheme 3. Formation of 2d and 2i. Reagents and conditions: (a) SOCl2, MeOH, r.t.,
overnight.2.4. Enzymatic activity assays
NO production experiments were performed using (bovine
recombinant) eNOS enzyme. NO Production was measured by the
well-established nitrate/nitrite – also called lactate dehydrogenase
(LDH) – colorimetric assay, which exploits the Griess reaction to
quantify the nitrites generated from NO.51 The concentrations of
NO-derived nitrites produced from 4a–j and 11a–c were higher
or comparable to that of L-arginine when incubated in the presence
of eNOS (Table 1). L-Arginine produced a 25 lM nitrites concentra-
tion, while for 4a, 4g, 4j and 11a–c higher concentrations of nitrites
were measured. The remaining compounds displayed NO produc-
tion similar to L-arginine. Dipeptide derivatives 4d and 4i werenot tested for enzymatic activity because – as explained below –
they did not polarise successfully.
2.5. SABRE hyperpolarisation
Hyperpolarization experiments were performed on 4a–j and
11a–c. All experiments were done in 0.6 mL of methanol-d4 in
Young tubes previously degassed and filled with pH2 with a pres-
sure of 3 bar.1,15 The catalyst precursor used was [Ir(COD)(IMes)
Cl] [COD = cyclooctadiene; IMes = 1,3-bis(2,4,6-trimethylphenyl)
imidazole-2-ylidene], since it was previously demonstrated that
this catalyst is one of the most versatile precursors for polarization
transfer.16 We used the so called ‘‘shake-and-drop” method,
according to which the sample was shaken for 10 s in a given mag-
netic field prior to dropping it into the NMR magnet and rapidly
acquiring the NMR spectrum.15 For these experiments a single
90 radiofrequency (RF) pulse was applied. All of the samples con-
tained a concentration of 40 mM of the ligand 4a–j or 11a–c and
5 mM of the catalyst precursor. Polarization transfer was per-
formed at both 65 G and Earth’s magnetic field (MF) in order to
study the effect of MF on the polarization transfer onto the ligands.
These MF were chosen based on literature reports.12,18,24
Scheme 4. Synthesis of second generation compounds 11a–c. Reagents and conditions: (a) 4-picolylamine, HATU, TEA, DCM, r.t., 5 h.; (b) CH3SO2Cl, Py, 40 C, 2 h; (c)
NH2OHHCl, K2CO3, EtOH, r.t., 1 h.; (d) HCl 4 M in dioxane, r.t., 1 h.; (e) SOCl2, MeOH, r.t., overnight; (f) Boc2O, TEA, DCM, r.t., 1.5 h.; (g) LiOH, THF/H2O 4:1, r.t., overnight; (h)
KOCN, HCl, 70 C, 1 h.; (i) Ac2O, NaOH, H2O, r.t., 3 h.
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MF allows the couplings J (between the hydrides and the acceptingScheme 5. Synthesis of L-citrulline derivatives 21a–c. Reagents and conditions: (a)
HCl 4 M in dioxane, r.t., 1 h; (b) 3-picolylamine, HATU, TEA, DCM, r.t., 5 h.; (c) 4-
aminopyridine, HATU, TEA, DCM, r.t., 5 h.protons) and the chemical shift difference between them to
become optimally aligned. The effect of a co-ligand was also stud-
ied. In this context, a co-ligand is a small molecule that has lower
binding affinity for the iridium catalyst centre than that of the
ligand to be hyperpolarized. When the residence time on iridium
is too long, the co-ligand can help driving dissociation of the
already hyperpolarized ligand, thereby enhancing the build-up rate
of this hyperpolarised agent in solution. In a second approach, the
co-ligand can enable the hyperpolarization of more bulky targets
which might not initially bind due to steric hindrance. The co-
ligand, being a small molecule, helps freeing up space on the irid-
ium centre to enable the bulky target to form an active catalyst.
Acetonitrile generally behaves as a good co-ligand for SABRE, and
in these experiments 2 lL of acetonitrile-d3 was used (final con-
centration of 60 mM) to avoid polarization being lost into acetoni-
trile protons during catalysis.
The signal enhancements obtained during this study can be
seen in Table 2. Generally, the 4-substituted pyridines hyperpolar-
ized better in the Earth’s MF, while the 3-substituted pyridines
showed better performance at 65 G. As expected, when hyperpo-
larizing with acetonitrile-d3 the results followed the trend that
bulkier molecules polarize slightly better in the presence of ace-
tonitrile-d3. Conversely, 4d and 4i–j, the dipeptides derivatives,
did not show any significant enhancement of signal, possibly due
to steric hindrance even when using a co-ligand. The second gen-
eration of compounds also failed to show good performance under
these SABRE conditions as only 11b was hyperpolarized, while 11a
and 11c failed to hyperpolarize significantly. We believe that the
hydroxyl-guanidyl group, despite being less basic than the guani-
dyl, may bind the metal in an even stronger manner, partially
Table 1
NO2 concentration produced by L-arginine, 4a–j and 11a–c after colorimetric LDH assay on eNOS.
Compound L-arginine 4a 4b 4c 4d 4e 4f 4g 4h 4i 4j 11a 11b 11c
[NO2] (lM) 25 48 20 21 N/Aa 22 22 26 23 N/Aa 38 26 29 27
a No enzymatic activity test was performed on 4d and 4i.
Table 2
Total NMR signal enhancements achieved for compounds 4a–j and 12a–c.a
Without acetonitrile-d3 With acetonitrile-d3
Magnetic field Earth’s MF 65 G Earth’s MF 65 G
4a 209 95 268 102
4b 26b 50b 162 147
4c 15 10 8 9
4d <1 <1 <1 <1
4e 870 297 322 261
4f 112 229 270 314
4g 36 23 43 26
4h 38 37 43 45
4i <1 <1 <1 <1
4j <1 <1 <1 <1
11a <1 <1 <1 <1
11b 51c 5 19c N/Ad
11c <1 <1 <1 <1
a Compounds were hyperpolarized in methanol-d4, with a parahydrogen pres-
sure = 3 bar, 10 s shaking time, [Ir(COD)(IMes)Cl] as catalyst precursor and con-
centrations of ligand and catalyst precursor of 40 mM and 5 mM respectively.
Experiments were done with and without 60 mM of acetonitrile-d3 as co-ligand and
at Earth’s MF and 65 G.
b Sample was partially deuterated.
c Experiments performed at 50 C.
d No experiment was performed under these conditions.
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forming compound in the SABRE experiment, giving the highest
enhancements (Fig. 2). The hyperpolarized 1H NMR spectrum (in
blue) can be compared to its thermal (in red), where thermal spec-
trum is vertically enlarged 32 times.
Two enhanced signals were expected, but four were actually
observed in the spectrum. Signals labelled as A and C on Fig. 2 cor-
respond to the free compound 4e in solution, while signals B and D
correspond to the fraction bound to the catalyst. The bound frac-
tion may readily be dissociated by using a catalyst deactivator,
such as bipyridine.26 Deactivation of the catalyst may be achieved
by adding a chelator to the solution, which is a molecule with a
high affinity for the iridium centre. The total enhancement for all
four observed enhanced signals was 870-fold, which would corre-
spond to only two peaks if the catalyst were deactivated. This cor-
responds to a 2.8% achieved polarization at 9.4 T. Hydride signals
can be observed in the d 21 to 24 region, indicating that as pro-
posed pH2 effectively enters the catalytic complex and is coupled
to the pyridine of the ligand to hyperpolarise.2.6. In vitro spectroscopy
The first in vitro spectroscopy attempt was performed using 4e,
i.e. the compound that showed the highest level of hyperpolarisa-
tion. The experiment was carried out under conditions used for an
optimal performance of the eNOS enzyme. The reaction was mon-
itored by NMR. The L-citrulline derivative 21cwas expected to give
similar, yet distinguishable, peaks to those of 4e with the maxi-
mum difference being 0.05 ppm in the aromatic region. Fig. 3
shows spectroscopically the fate of analogue 4e after 3 h of reac-
tion. Signals A and C correspond to 4e and after 25 min new signals
B and D started to form, with a 41% conversion after 3 h. However,
HPLC analysis of the crude enzymatic mixture revealed thatL-arginine and 4-aminopyridine were the main components of
the mixture. Further analyses showed that peaks B and D belong
to 4- aminopyridine, as confirmed independently by recording
the spectrum of 4-aminopyridine alone (not shown), and that –
to our surprise – compound 4e was simply being hydrolysed by
the PBS buffer solution, even in the absence of eNOS.
Analogues 4a and 4f also gave good levels of hyperpolarisation
(268 and 270-fold enhancement respectively), therefore investiga-
tion of their suitability for NMR spectroscopy was carried out next.
Both 4a and 4f proved to be stable under the reaction conditions
overnight. However, when PBS buffered D2O solutions of a 1:1 mix-
ture of 4a or 4f and their corresponding citrulline derivatives 21a
and 21b respectively were analysed by 1H NMR spectroscopy at
400 MHz we could not discriminate between enzymatic product
and starting material via peaks in the aromatic peaks region which
would receive SABRE hyperpolarisation.
Gratifyingly, when a 2D COSY or NOESY spectrum of a 1:1 mix-
ture of 4f and the enzymatic product 21b was recorded, the amino
acid back-bone signals can be distinguished as they exhibit chem-
ical shift differences of 48 Hz and 46 Hz at a field of 9.4 T, while the
corresponding benzylic protons appear as a singlet at d 4.60 and an
AB doublet at d 4.57 and 4.68 respectively (Fig. 4). Hence, selective
excitation of the overlapping signals at d 8.70 for the H-5 ring pro-
tons of the pyridyl unit of 4f in conjunction with 1D COSY or NOE
methods enabled the observation of a resolved connection to the
distinguished benzylic protons. It is worth noting that similar 1D
COSY methods have been used by Tessari et al. to establish the
magnitude of hydride substrate couplings in the catalyst,52 whilst
use of the NOE approach has been described by some of us.5 The
ratio of these peaks is proportional to the amount of material in
solution. Hence, this enhanced hyperpolarized response can be
used to probe NO production in vitro by 1H NMR spectroscopy.
Finally, relaxation times T1 ranging from 2.0 to 3.6 s were exper-
imentally determined by 1H NMR in physiological conditions for
selected pyridyl protons of compounds 4a,e,f (Fig. 5). Although
these T1 values are currently too low for in vivo MRI applications
of these probes (T1 of at least 8–10 s would be required to guaran-
tee sufficient polarization half-life), it is known that deuteration of
adjacent protons could significantly increase T1 values,6 therefore
deuterated versions of molecules 4 might be viable probes for
future in vivo studies.
3. Conclusions
Novel eNOS substrates, L-arginine or L-NOHA analogues incor-
porating a pyridyl group, have been successfully synthesised for
SABRE hyperpolarization. Compounds 4a–j and 11a–c showed a
comparable or higher NO production by eNOS than L-arginine.
Polarization transfer by SABRE was optimized to yield a maximum
hyperpolarization of 870-fold enhancement on 4e. In vitro spec-
troscopy was successfully carried out in the presence of eNOS,
and a future application of MRI spectroscopy for imaging NO pro-
duction using SABRE-hyperpolarised tracers in vivomight be possi-
ble, provided further increase of both hyperpolarisation – for
achieving sufficient signal-to-noise ratio – and T1 – for achieving
sufficiently long hyperpolarization half-life – can be achieved.
The potential to resolve such a reaction in vivo depends on how
the relaxation times of these resonances respond to the biochemi-
Fig. 2. Hyperpolarized 1H spectrum for 4e (in blue) compared to its thermal 1H spectrum (in red). Thermal spectrum is vertically enlarged by 32 times. Four hyperpolarized
signals can be observed: A and C correspond to the free compound in solution, while B and D are those of the fraction bound to the catalyst.
Fig. 3. Analogue 4e was unstable during in vitro spectroscopy test, as the amide bond was cleaved producing L-arginine and 4-aminopyridine. Signals A and C belong to
compound 4e, while B and D correspond to 4-aminopyridine.
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in vivo is also possible with hyperpolarised agents and hence
should further tests reveal this to be a problem we expect to be
able to harness a 13C labelling strategy to ensure success with these
agents. To our knowledge, the library of compounds reported
herein is the first attempt to develop SABRE-hyperpolarised tracers
for quantification of NO production.4. Experimental section
1H (400.13 MHz), 13C (100.58 MHz) NMR spectra were recorded
on a Bruker ADVANCE III spectrometer. 1H NMR chemical shifts are
reported relative to TMS, and the solvent resonance was employed
as the internal standard (CDCl3 d = 7.26, MeOD d = 3.31, D2O
d = 4.79, DMSO-d6 d = 2.50). 13C NMR spectra were recorded with
complete proton decoupling, and the chemical shifts are reported
relative to TMS with the solvent resonance as the internal standard
(CDCl3, d = 77.0, MeOD d = 49.00, DMSO-d6 d = 39.52). The follow-ing abbreviations are used to describe spin multiplicity: s = singlet,
d = doublet, dd = doublet-doublet, dt = doublet-triplet, t = triplet,
q = quartet, m = multiplet, bs = broad singlet. All chemical shifts
(d) are expressed in parts per million and coupling constants (J)
are given in Hertz. LC–MS experiments were performed on an Agi-
lent Technologies 1200 Series HPLC system equipped with a DAD
and a 6120 MS detector composed by a ESI ionization source and
a Single Quadrupole mass selective detector using an Analytical
C18 RP Column (Phenomenex Luna C18 (2), 250  4.60 mm,
5 lm, 100 Å). HPLC purifications were performed on an Agilent
1260 system using a semi preparative C18 RP Column (Phenom-
enex Luna C18 (2), 250  10.00 mm, 5 lm, 100 Å). Optical rotation
values were measured on an AA-65 Angular Scale automatic
polarimeter (Optical Activity Limited) with a 1 dm cell at the
sodium D line. Samples were freeze-dried on an Edwards Modulyo
freeze drier. All commercially available reagents were used as
received. Reactions were magnetically stirred and monitored by
TLC on silica gel (60 F254 pre-coated glass plates, 0.25 mm thick-
ness). Visualization was accomplished by irradiation with a UV
Fig. 4. 1D COSY corresponding to the benzylic methylene of a 1:1 mixture of 4f and the corresponding citrulline derivative 21b when overlapping aromatic signals at d 8.70
are irradiated. Signals A, B, D and E correspond to 4f, whilst signal C belong to 21b. The broad signal at d 4.70 is a solvent artefact.
Fig. 5. T1 relaxation times (in seconds) for pyridyl protons in compounds 4a,e,f at
pH = 7.4 and 37 C.
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sium permanganate solution. Flash chromatography was per-
formed on silica gel (60 Å, particle size 0.040–0.062 mm). Yields
refer to chromatographically and spectroscopically pure com-
pounds, unless stated otherwise. Abbreviations used: DCM for
dichloromethane, EtOAc for ethyl acetate, Et2O for diethyl ether,
MeOH for methanol, THF for tetrahydrofuran, MeOD for deuterated
methanol, HATU for 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, TEA for
triethylamine, TFA for trifluoroacetic acid, Boc for tert-butyloxycar-
bonyl, Pbf for 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.4.1. General procedure for the synthesis of compounds 2d and 2i
A solution of the corresponding pyridyl-L-alanine (150 mg;
0.90 mmol) in 2.5 mL of methanol was cooled down to 10 C.
SOCl2 (328 mL; 4.51 mmol) was added dropwise and the mixture
stirred at r.t. for 36 h. Solvent was evaporated to yield the dihy-
drochloride products in 90%-quantitative yields.4.1.1. Methyl (2S)-2-amino-3-(pyridin-4-yl)propanoate (2d)
Precursor was 3-(4-pyridyl)-L-alanine 5. Final product was a
white solid (202 mg; 90%). Rf 0.5 (DCM/MeOH 9:1); 1H NMR
(D2O, 400 MHz) d 8.70–8.71 (d, J = 7.0 Hz, 2H), 7.97–7.99 (d,
J = 6.1 Hz, 2H), 4.60–4.63 (t, J = 7.2 Hz, 1H), 3.73 (s, 3H), 3.56–
3.62 (dd, J = 14.6, 8.0 Hz, 1H), 3.48–3.53 (dd, J = 14.6, 6.6 Hz, 1H);
13C NMR (D2O, 100 MHz) d 168.9, 156.4, 141.3, 128.1, 53.8, 52.2,
35.4; MS (ESI), m/z calculated for [C9H12N2O2+H+] = 181.1, found
181.1; [a]D20 in CH3OH = +29.0 (c = 1.0).4.1.2. Methyl (2S)-2-amino-3-(pyridin-3-yl)propanoate (2i)
Precursor was 3-(3-pyridyl)-L-alanine 6. Final product was a
white solid (226 mg, quantitative). Rf 0.5 (DCM/MeOH 9:1); 1H
NMR (D2O, 400 MHz) d 8.73 (m, 1H), 8.67–8.6 9 (d, J = 5.6 Hz,
1H), 8.51–8.53 (d, J = 8.2 Hz, 1H), 7.98–8.02 (dd, J = 8.1, 5.9 Hz,
1H), 4.50–4.54 (t, J = 7.2 Hz, 1H), 3.69 (s, 3H), 3.49–3.55 (dd,
J = 14.8, 7.7 Hz, 1H), 3.40–3.45 (dd, J = 14.8, 6.6 Hz, 1H); 13C (D2O,
100 MHz) d 168.9, 148.1, 141.6, 140.5, 135.4, 127.6, 53.9, 52.7,
32.3; MS (ESI), m/z calculated for [C9H12N2O2+H+] = 181.1, found
181.1; [a]D20 in CH3OH = +22.0 (c = 1.0).4.2. General procedure for the synthesis of compounds 3a–i
To a solution of the amino acid Boc-L-Arg(Pbf)-OH (1 eq.;
150 mg; 0.28 mmol) in DCM (1.5 mL) was added, in the stated
order, HATU (1.4 eq.; 152 mg; 0.40 mmol), TEA (2.9 eq.; 116 lL;
0.83 mmol) and the corresponding aminopyridine (1.2 eq.), unless
stated otherwise. These mixtures were stirred at r.t. for 5 h. Crude
mixtures were washed with HCl 1 M, sat. NaHCO3 and brine, dried
over anhydrous Na2SO4, filtered and solvent evaporated. The
remaining residues were purified by flash chromatography using
a DCM/MeOH 94:6 mixture as solvent in 52–94% yield.4.2.1. tert-Butyl-N-[(1S)-4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-
benzo-5-furanyl)sulfonyl]carbamimidamido}-1-[(4-
pyridinylmethyl)carbamoyl]butyl]carbamate (3a)
Aminopyridine used was 4-(aminomethyl)pyridine 2a (35 lL;
0.34 mmol). Final product was a white solid (91 mg; 53%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.41–8.42 (d,
J = 5.6 Hz, 2H), 7.73 (bs, 1H), 7.12–7.13 (m, 2H), 6.11 (bs, 2H),
5.50–5.52 (m, 1H), 4.35–4.40 (dd, J = 15.8, 5.7 Hz, 1H), 4.26–4.32
(dd, J = 15.8, 5.9 Hz, 1H), 4.20 (m, 1H), 3.13–3.23 (m, 2H), 2.87 (s,
2H), 2.47 (s, 3H), 2.39 (s, 3H), 2.01 (s, 3H), 1.75–1.79 (m, 1H),
1.52–1.54 (m, 3H),1.39 (s, 6H), 1.34 (s, 9H); 13C NMR (CDCl3,
100 MHz) d 173.3, 158.9, 156.6, 156.1, 149.5, 148.1, 138.3, 132.5,
132.2, 124.8, 122.3, 117.7, 86.5, 79.9, 54.1, 43.2, 42.0, 40.2, 30.0,
29.7, 28.6, 28.3, 28.3, 25.7, 19.3, 18.0, 12.5; MS (ESI),m/z calculated
for [C30H44N6O6S+H+] = 617.3, found 617.2; [a]D20 in CHCl3 = +7.0
(c = 1.0).
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benzo-5-furanyl)sulfonyl]carbamimidamido}-1-{[1-(pyridine-4-yl)
ethyl]carbamoyl}butyl]carbamate (3b)
Aminopyridine used was 4-(1-aminoethyl)pyridine 2b (41 lL;
0.34 mmol). Final product was a white solid (130 mg; 74%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.47–8.51 (m,
2H), 7.76–7.86 (m, 1H), 7.25 (m, 2H), 6.33 (bs, 3H), 5.78–5.85 (m,
1H), 4.97–5.02 (q, J = 6.9 Hz, 1H), 4.26 (m, 1H), 3.23 (m, 2H), 2.97
(s, 1H), 2.59 (s, 3H), 2.51 (s, 3H), 2.11 (s, 3H), 1.63–1.80 (m, 1H),
1.53–1.55 (m, 3H), 1.41–1.48 (m, 18H); 13C NMR (CDCl3,
100 MHz) d 173.3, 173.1, 158.5, 156.7, 156.4, 154.3, 148.8, 148.6,
138.0, 133.0, 132.1, 124.6, 121.6, 117.1, 86.3, 79.3, 54.4, 42.6,
40.0, 29.2, 29.0, 27.4, 25.7, 20.3, 20.2, 18.2, 17.1, 11.2; MS (ESI)
m/z calculated for [C31H46N6O6S+H+] = 631.3, found 631.2.
4.2.3. tert-butyl-N-[(1S)-1-[methyl(pyridine-4-ylmethyl)carbamoyl]-
4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-
yl)sulfonyl]carbamimidamido}butyl]carbamate (3c)
Aminopyridine used was 4-[(methylamino)methyl]pyridine 2c
in its dihydrochloride salt (66 mg; 0.34 mmol). 4.9 eq. of TEA
(191 lL; 1.37 mmol) were added instead. Forms rotamers giving
multiple peaks on the NMR. 1H NMR spectrum was acquired at
80 C. 13C NMR reported is acquired at 25 C. Final product was a
white solid (121 mg; 69%). Rf 0.5 (DCM/MeOH 9:1); 1H NMR
(DMSO-d6, 400 MHz, 80 C) d 8.50–8.51 (m, 2H), 7.19–7.20 (m,
2H), 6.54–6.58 (bs, 2H), 6.43 (s, 2H), 4.59–4.63 (m, 2H), 4.40–
4.41 (m, 1H), 2.97–3.08 (m, 10 H), 2.47 (s, 3H), 2.04 (s, 3H),
1.48–1.64 (m, 4H), 1.43 (s, 6H), 1.39 (s, 9H); 13C NMR (CDCl3,
100 MHz) d 172.8, 158.7, 156.3, 156.2, 155.8, 150.3, 150.1, 145.8,
145.6, 138.3, 133.0, 132.2, 124.6, 122.4, 121.7, 117.5, 86.4, 80.1,
52.3, 50.6, 49.9, 43.2, 40.8, 35.3, 34.4, 30.8, 30.4, 28.6, 28.3, 28.2,
25.0, 24.9, 19.3, 17.9, 12.5; MS (ESI) m/z calculated for [C31H46N6-
O6S+H+] = 631.3, found 631.2; [a]D20 in CHCl3 = 0 (c = 1.0).
4.2.4. Methyl (2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-5-{1-
[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]
carbamimidamido}pentanamido]-3-(pyridin-4-yl)propanoate (3d)
Aminopyridine used was methyl (2S)-2-amino-3-(4-pyridinyl)
propanoate 2d (61 mg; 0.34 mmol). Final product was a white solid
(100 mg; 52%). Rf 0.6 (DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz)
d 8.36–8.38 (m, 2H), 7.60 (bs, 1H), 7.05–7.07 (m, 2H), 6.04–6.25
(bs, 3H), 5.55–5.57 (m, 1H), 4.73–4.78 (q, J = 7.3 Hz, 1H), 4.10 (m,
1H), 3.63 (s, 3H), 3.08–3.13 (m, 3), 2.93–2.99 (m, 1H), 2.88 (s,
2H), 2.50 (s, 3H), 2.43 (s, 3.15), 2.02 (s, 3H), 1.66 (m, 1H), 1.43–
1.66 (m, 3H), 1.38 (s, 6H), 1.32 (s, 9H); 13C NMR (CDCl3,
100 MHz) d 172.7, 171.5, 158.8, 156.5, 155.9, 149.6, 146.1, 138.3,
132.7, 132.2, 124.7, 117.6, 86.4, 79.9, 53.9, 52.6, 52.5, 43.2, 40.4,
36.7, 29.9, 28.6, 28.3, 25.4, 19.3, 18.0, 12.5; MS (ESI)m/z calculated
for [C33H48N6O8S+H+] = 689.3, found 689.2; [a]D20 in CHCl3 = -2.0
(c = 1.0).
4.2.5. tert-Butyl-N-[(1S)-4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-
benzofuran-5-yl)sulfonyl]carbamimidamido}-1-[(pyridine-4-
yl)carbamoyl]butyl]carbamate (3e)
Aminopyridine used was 4-aminopyridine 2e (32 mg;
0.34 mmol). Final product was a white solid (104 mg; 62%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 9.68 (bs, 1H),
8.44–8.45 (d, J = 6.1 Hz, 2H), 7.64 (m, 2H), 6.26 (bs, 2H), 5.67–
5.69 (m, 1H), 4.59 (m, 1H), 3.33 (m, 2H), 2.98 (s, 2H), 2.61 (s,
3H), 2.54 (s, 3H), 2.12 (s, 3H), 1.93 (m, 1H), 1.69 (m, 3H), 1.49 (s,
6H), 1.45 (s, 9H); 13C NMR (CDCl3, 100 MHz) d 172.4, 159.0,
156.6, 156.2, 150.2, 145.7, 138.4, 132.3, 132.2, 124.9, 117.8,
114.2, 86.6, 80.2, 54.6, 43.2, 40.2, 29.7, 28.6, 28.3, 25.7, 19.4,
18.0, 12.5; MS (ESI) m/z calculated for [C29H42N6O6S+H+] = 603.3,
found 603.2; [a]D20 in CHCl3 = +6.0 (c = 1.0).4.2.6. tert-Butyl N-[(1S)-4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-
benzofuran-5-yl)sulfonyl]carbamimidamido}-1-[(pyridine-3-
ylmethyl)carbamoyl]butyl]carbamate (3f)
Aminopyridine used was 3-(aminomethyl)pyridine 2f (35 lL;
0.34 mmol). Final product was a white solid (162 mg; 94%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.47 (s, 1H), 8.40–
8.41 (m, 1H), 7.97 (bs, 1H), 7.58–7.60 (m, 1H), 7.16–7.19 (dd,
J = 4.9, 7.6 Hz, 1H), 6.42 (bs, 3H), 5.85–5.87 (m, 1H), 4.38–4.43
(dd, J = 5.9, 15.3 Hz, 1H), 4.31–4.36 (dd, J = 5.9, 15.3 Hz, 1H), 4.21
(m, 1H), 3.12–3.26 (m, 2H), 2.94 (s, 2H), 2.54 (s, 3H), 2.46 (s, 3H),
2.08 (s, 3H), 1.78–1.80 (m, 1H), 1.51–1.61 (m, 3H), 1.46 (s, 6H),
1.37 (s, 9H); 13C NMR (CDCl3, 100 MHz) d 173.1, 158.9, 156.6,
156.0, 148.7, 148.2, 138.3, 135.6, 134.4, 132.6, 132.2, 124.7,
123.6, 117.6, 86.5, 79.8, 53.9, 43.2, 40.7, 40.2, 30.1, 29.7, 28.6,
28.3, 25.7, 19.3, 18.0, 12.5; MS (ESI) m/z calculated for [C29H42N6-
O6S+H+] = 617.3, found 617.2; [a]D20 in CHCl3 = -5.0 (c = 1.0).
4.2.7. tert-Butyl N-[(1S)-4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-
benzofuran-5-yl)sulfonyl]carbamimidamido}-1-{[1-(pyridine-3-yl)
ethyl]carbamoyl}butyl]carbamate (3g)
Aminopyridine used was 3-(1-aminoethyl)pyridine 2g (41 lL;
0.34 mmol). Final product was a white solid (132 mg; 75%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.50 (s, 1H), 8.36–
8.37 (m, 1H), 7.81–7.91 (m, 1H), 7.61 (m, 1H), 7.12–7.18 (m, 1H),
6.39 (bs, 3H), 5.85–5.95 (m, 1H), 4.95–4.98 (m, 1H), 4.12–4.18
(m, 1H), 3.14–3.37 (m, 2H), 2.91 (s, 2H), 2.53 (s, 3H), 2.46 (s, 3H),
2.05 (s, 3H), 1.57–1.71 (m, 4H), 1.42 (s, 9H), 1.33–1.35 (m, 9H);
13C NMR (CDCl3, 100 MHz) d 172.1, 158.8, 156.6, 156.6, 156.0,
148.1, 148.1, 147.9, 147.6, 139.6, 139.3, 138.3, 138.3, 134.2,
134.1, 132.7, 132.2, 130.9, 128.8 124.7, 123.6, 123.6, 117.6, 86.4,
79.8, 53.8, 47.1, 43.2, 40.4, 29.7, 28.6, 28.3, 28.3, 25.6, 21.8, 21.6,
19.4, 18.0, 12.5; MS (ESI) m/z calculated for [C31H46N6O6S+H+]
= 631.3, found 631.2.
4.2.8. tert-Butyl N-[(1S)-1-[methyl(pyridine-3-ylmethyl)carbamoyl]-
4-{1-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-
yl)sulfonyl]carbamimidamido}butyl]carbamate (3h)
Aminopyridine used was 3-[(methylamino)methyl]pyridine 2h
(42 lL; 0.34 mmol). Forms rotamers. 1H NMR spectrum was
acquired at 80 C. 13C NMR reported is acquired at 25 C. Final pro-
duct was a white solid (132 mg; 75%). Rf 0.5 (DCM/MeOH 9:1); 1H
NMR (DMSO-d6, 400 MHz, 80 C) d 8.48 (m, 2H), 7.61–7.63 (d,
J = 7.8 Hz, 1H), 7.31–7.34 (dd, J = 4.7, 7.6 Hz, 1H), 6.43–6.58 (m,
4H), 4.40–4.63 (m, 3H), 3.05–3.09 (m, 4H), 2.95–2.97 (m, 5H),
2.47 (s, 3H), 2.04 (s, 3H), 1.47–1.66 (m, 4H), 1.44 (s, 6H), 1.39 (s,
9H); 13C NMR (CDCl3, 100 MHz) d 172.6, 158.7, 156.3, 156.1,
149.2, 149.0, 148.5, 138.3, 135.7, 134.8, 133.0, 132.4, 132.2,
131.8, 130.9, 128.8, 124.6, 123.8, 117.4, 86.4, 80.0, 50.9, 49.9,
49.1, 43.2, 40.8, 35.0, 34.0, 30.8, 30.5, 28.6, 28.3, 28.3, 24.9, 19.3,
17.9, 12.5; MS (ESI) m/z calculated for [C31H46N6O6S+H+] = 631.3,
found 631.2; [a]D20 in CHCl3 = -6.0 (c = 1.0).
4.2.9. Methyl (2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-5-{1-
[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-
yl)sulfonyl]carbamimidamido}pentanamido]-3-(pyridine-3-yl)
propanoate (3i)
Amounts used were doubled: Boc-L-Arg(Pbf)-OH (300 mg;
0.57 mmol), HATU (304 mg; 0.80 mmol), TEA (232 lL; 1.66 mmol),
methyl (2R)-2-amino-3-(3-pyridinyl)propanoate 2i (122 mg;
0.68 mmol).White solid (237 mg; 60%). Rf 0.6 (DCM/MeOH 9:1);
1H NMR (CDCl3, 400 MHz) d 8.40–8.42 (m, 2H), 7.63–7.65 (bs,
1H), 7.56–7.58 (d, J = 7.8 Hz, 1H), 7.19–7.22 (dd, J = 7.8, 4.9 Hz,
1H), 6.30–6.53 (bs, 3H), 5.79–5.80 (bs, 1H), 4.77–4.83 (m, 1H),
4.12 (m, 1H), 3.70 (s, 3H), 3.17–3.22 (m, 3H), 2.99–3.05 (m, 1H),
2.96 (s, 2H), 2.60 (s, 3H), 2.52 (s, 3H), 2.10 (s, 3H), 1.55–1.73 (m,
4H), 1.47 (s, 6H), 1.39 (s, 9H); 13C NMR (CDCl3, 100 MHz) d 172.6,
2738 F. Fernandez Diaz-Rullo et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2730–2742171.5, 158.8, 156.5, 155.8, 150.2, 147.9, 138.4, 137.3, 132.8, 132.6,
132.3, 124.7, 123.6, 117.6, 86.4, 79.9, 54.3, 53.1, 52.5, 43.2, 40.4,
34.7, 29.7, 28.6, 28.3, 25.5, 19.3, 18.0, 12.5; MS (ESI) m/z calculated
for [C31H46N6O6S+H+] = 689.3, found 689.2; [a]D20 in CHCl3 = -5.0
(c = 1.0).
4.3. General procedure for the synthesis of compounds 4a–i
Precursor was dissolved in 1 mL of TFA and stirred at r.t. for 2 h,
unless stated otherwise. Solvent was evaporated under a current of
air, triturated with Et2O, dissolved in water and passed through a
Sep-Pak Plus C18 cartridge previously conditioned by passing
methanol (10 mL) followed by water (10 mL). Solvent was finally
freeze dried and TFA salt exchanged to HCl salt by adding some
drops of HCl 2 M prior to freeze-drying. Products were obtained
in 38%-quant yield.
4.3.1. (2S)-2-Amino-5-carbamimidamido-N-(pyridin-4-ylmethyl)
pentanamide (4a)
Precursor was 3a (63 mg; 0.10 mmol). Final product was a
white solid (27 mg; quant.). 1H NMR (D2O, 400 MHz) d 8.67–8.68
(d, J = 6.4 Hz, 2H), 7.90–7.92 (d, J = 6.2 Hz, 2H), 4.12–4.15 (t,
J = 6.5 Hz, 1H), 3.18–3.21 (t, J = 6.7 Hz, 2H), 1.91–1.98 (quin,
J = 6.9 Hz, 2H), 1.59–1.66 (quin, J = 7.4 Hz, 2H); 13C NMR (D2O,
100 MHz) d 170.3, 159.4, 156.8, 141.1, 125.3, 52.9, 42.7, 40.3,
28.0, 23.7; MS (ESI) m/z calculated for [C12H20N6O+H+]
= 265.1699, found 265.1774; [a]D20 in CH3OH = +10.0 (c = 1.0).
4.3.2. (2S)-2-Amino-5-carbamimidamido-N-[1-(pyridin-4-yl)ethyl]
pentanamide (4b)
Precursor was 3b (102 mg; 0.16 mmol). Final product was a
white solid (39 mg; 87%). Two different diastereoisomers, both
reported. Minor diastereoisomer is marked with an asterisk (⁄)
on spectra. Major diastereoisomer: 1H NMR (D2O, 400 MHz) d
8.66–8.67 (d, J = 6.7 Hz, 2H), 7.92–7.95 (m, 2H), 5.06–5.11 (m,
1H), 4.02–4.07 (m, 1H), 3.10–3.14 (t, J = 6.8 Hz, 2H), 1.82–1.92
(m, 2H), 1.57–1.65 (m, 1H), 1.46–1.48 (m, 4H). Minor diastereoiso-
mer: 1H NMR (D2O, 400 MHz) d 8.63–8.65 (d, J = 6.7 Hz, 2H), 7.92–
7.95 (m, 2H), 5.06–5.11 (m, 1H), 4.02–4.07 (m, 1H), 3.15–3.18 (t,
J = 6.8 Hz, 2H), 1.82–1.92 (m, 2H), 1.57–1.65 (m, 1H), 1.46–1.48
(m, 4H); 13C NMR (D2O, 100 MHz) d 169.4, 169.3, 164.0, 163.9,
156.7, 156.7, 141.5, 141.3, 124.6, 124.5, 52.8, 52.6, 49.8, 49.7,
40.3, 40.3, 28.0, 23.8, 23.4, 20.1, 19.9; MS (ESI) m/z calculated for
[C12H20N6O+H+] = 279.1855, found 279.1927; [a]D20 in CH3OH =
+7.0 (c = 1.0).
4.3.3. (2S)-2-Amino-5-carbamimidamido-N-methyl-N-(pyridin-4-
ylmethyl)pentanamide (4c)
Precursor was 3c (104 mg; 0.16 mmol). Final product was a
white solid (27 mg; 59%). Product forms rotamers. 1H NMR spec-
trum reported was acquired at 80 C. 13C NMR spectrum was
acquired at 25 C. 1H NMR (D2O, 400 MHz) d 9.24–9.25 (d,
J = 6.1 Hz, 2H), 8.24–8.25 (m, 2H), 5.20 (m, 1H), 3.83–3.86 (t,
J = 6.2 Hz, 2H), 3.78 (s, 3H), 2.57–2.59 (m, 2H), 2.30–2.32 (m,
2H); 13C NMR (D2O, 100 MHz) d 170.4, 163.1, 162.7, 158.1, 156.8,
141.6, 141.2, 125.2, 125.0, 117.8, 114.9, 51.6, 50.5, 40.3, 36.1,
26.9, 23.4; MS (ESI) m/z calculated for [C12H20N6O+H+]
= 279.1981, found 279.2053; [a]D20 in CH3OH = +20.0 (c = 1.0).
4.3.4. Methyl (2S)-2-[(2S)-2-amino-5-
carbamimidamidopentanamido]-3-(pyridin-4-yl)propanoate (4d)
Precursor was 3d (79 mg; 0.11 mmol). Final product was a
white solid (14 mg; 38%). 1H NMR (D2O, 400 MHz) d 8.64–8.65
(d, J = 6.3 Hz, 2H), 7.92–7.94 (d, J = 6.2 Hz, 2H), 4.97–5.01 (dd,
J = 9.1, 5.7 Hz, 1H), 3.94–3.97 (t, J = 6.3 Hz, 2H), 3.70 (s, 3H),
3.55–3.60 (dd, J = 14.6, 5.5 Hz, 1H), 3.30–3.36 (dd, J = 14.6, 9.3 Hz,1H), 3.15–3.18 (t, J = 6.7 Hz, 2H), 1.83–1.89 (q, J = 7.7 Hz, 2H),
1.55–1.64 (m, 2H); 13C NMR (D2O, 100 MHz) d 171.6, 169.6,
158.7, 156.8, 140.8, 127.9, 53.3, 52.5, 52.3, 40.3, 36.4, 28.0, 23.4;
MS (ESI) m/z calculated for [C15H24N6O3+H+] = 337.1910, found
337.1984; [a]D20 in CH3OH = +4.0 (c = 1.0).4.3.5. (2S)-2-Amino-5-carbamimidamido-N-(pyridin-4-yl)
pentanamide (4e)
Precursor was 3e (88 mg; 0.15 mmol). Final product was a
white solid (26 mg; 71%). 1H NMR (D2O, 400 MHz) d 8.56–8.58
(d, J = 6.8 Hz, 2H), 8.10–8.11 (d, J = 6.7 Hz, 2H), 4.28–4.31 (t,
J = 6.1 Hz, 1H), 3.17–3.21 (t, J = 6.6 Hz, 2H), 1.97–2.10 (m, 2H),
1.69–1.71 (m, 2H); 13C NMR (D2O, 100 MHz) d 169.7, 156.7,
152.5, 142.0, 115.9, 53.9, 40.2, 27.6, 23.4; MS (ESI) m/z calculated
for [C11H18N6O+H+] = 251.1542, found 251.1616; [a]D20 in CH3-
OH = +24.0 (c = 1.0).4.3.6. (2S)-2-Amino-5-carbamimidamido-N-(pyridin-3-ylmethyl)
pentanamide (4f)
Precursor was 3f (154 mg; 0.25 mmol). Final product was a
white solid (61 mg; 92%). 1H NMR (D2O, 400 MHz) d 8.67 (s, 1H),
8.63–8.64 (d, J = 5.7 Hz, 1H), 8.45–8.47 (d, J = 8.1 Hz, 1H), 7.95–
7.98 (dd, J = 5.8, 7.7 Hz, 1H), 4.58–4.62 (d, J = 15.9 Hz, 1H), 4.51–
4.55 (d, J = 15.9 Hz, 1H), 3.99–4.02 (t, J = 6.5 Hz, 1H), 3.10–3.13 (t,
J = 6.9 Hz, 2H), 1.82–1.89 (m, 2H), 1.49–1.56 (m, 2H); 13C NMR
(D2O, 100 MHz) d 170.0, 162.2–163.3 (q, JC-F = 35.0 Hz), 156.7
146.0, 140.2, 140.0, 138.3, 127.4, 112.0–120.7 (q, JC-F = 290.7 Hz),
52.8, 40.2, 40.1, 27.9, 23.6; MS (ESI) m/z calculated for
[C12H20N6O+H+] = 265.1699, found = 265.1762; [a]D20 in CH3OH =
+23.0 (c = 1.0).4.3.7. (2S)-2-Amino-5-carbamimidamido-N-[1-(pyridin-3-yl)ethyl]
pentanamide (4g)
Precursor was 3g (115 mg; 0.18 mmol). Final product was a
white solid (51 mg; quant.). Two different diastereoisomers, both
reported. Minor diastereoisomer is marked with an asterisk (⁄)
on spectra. Major diastereoisomer: 1H NMR (D2O, 400 MHz) d
8.75 (s, 1H), 8.67–8.68 (d, J = 5.7 Hz, 1H), 8.54–8.56 (d, J = 8.1 Hz,
1H), 7.98–8.04 (m, 1H), 5.10–5.15 (q, J = 7.0 Hz, 1H), 3.98–4.01
(m, 1H), 3.08–3.11 (t, J = 6.8 Hz, 2H), 1.78–1.84 (q, J = 7.8 Hz, 2H),
1.52 (s, 3H), 1.35–1.47 (m, 2H); 13C NMR (D2O, 100 MHz) d 169.2,
156.7, 144.7, 143.2, 140.4, 139.4, 127.7, 52.6, 47.4, 40.2, 28.0,
23.8, 20.1. Minor diastereoisomer: 1H NMR (D2O, 400 MHz) d
8.73 (s, 1H), 8.63–8.65 (d, J = 5.7 Hz, 1H), 8.54–8.56 (d, J = 8.1 Hz,
1H), 7.98–8.04 (m, 1H), 5.10–5.15 (q, J = 7.0 Hz, 1H), 3.98–4.01
(m, 1H), 3.17–3.20 (t, J = 6.8 Hz, 2H), 1.87–1.93 (q, J = 7.8 Hz, 2H),
1.59–1.66 (m, 2H), 1.53 (s, 3H); 13C NMR (D2O, 100 MHz) d 169.2,
156.8, 144.8, 143.1, 140.1, 139.2, 127.5, 52.8, 40.3, 28.0, 23.6,
19.8; MS (ESI) m/z calculated for [C13H22N6O+H+] = 279.1855,
found 279.1928; [a]D20 in CH3OH = +12.0 (c = 1.0).4.3.8. (2S)-2-Amino-5-carbamimidamido-N-methyl-N-(pyridin-3-
ylmethyl)pentanamide (4h)
Precursor was 3h (114 mg; 0.18 mmol). Final product was a
white solid (50 mg; quant.). Product forms rotamers, 1H NMR spec-
trum reported was acquired at 80 C. 13C was acquired at 25 C. 1H
NMR (D2O, 400 MHz, 80 C) d 9.29–9.31 (m, 2H), 9.07–9.09 (d,
J = 8.1 Hz, 1H), 8.63–8.66 (m, 1H), 5.43–5.47 (d, J = 15.8 Hz, 1H),
5.26–5.30 (d, 15.8 Hz, 1H), 5.12–5.15 (t, J = 6.1 Hz), 3.77–3.81 (t,
J = 6.8 Hz, 2H), 3.74 (s, 3H), 2.49–2.54 (m, 2H), 2.20–2.28 (m,
2H); 13C NMR (D2O, 100 MHz) d 170.7, 157.7, 147.1, 141.2, 140.9,
137.7, 128.4, 51.4, 49.8, 41.2, 36.6, 27.8, 24.1; HRMS (ESI) m/z cal-
culated for [C13H22N6O+H+] = 279.1855, found 279.1918; [a]D20 in
CH3OH = +24.0 (c = 1.0).
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carbamimidamidopentanamido]-3-(pyridin-3-yl)propanoate (4i)
Precursor was 3i (201 mg; 0.29 mmol). Final product was a
white solid (85 mg; 86%). 1H NMR (D2O, 400 MHz) d 8.68 (s, 1H),
8.62–8.63 (d, J = 5.6 Hz, 1H), 8.47–8.49 (d, J = 7.8 Hz, 1H), 7.94–
7.98 (m, 1H), 4.86–4.90 (dd, J = 8.7, 5.7 Hz, 1H), 3.95–3.98 (t,
J = 6.3 Hz, 1H), 3.67 (s, 3H), 3.44–3.49 (dd, J = 14.6, 5.4 Hz, 1H),
3.22–3.28 (dd, J = 14.6, 8.9 Hz, 1H) 3.12–3.16 (t, J = 6.6 Hz, 2H),
1.81–1.87 (m, 2H), 1.52–1.61 (m, 2H); 13C NMR (D2O, 100 MHz) d
171.6, 169.6, 156.7, 147.8, 141.2, 139.9, 137.2, 127.3, 53.3, 52.8,
52.6, 40.4, 33.2, 28.0, 23.4; MS (ESI) m/z calculated for
[C12H20N6O+H+] = 337.1910, found 337.1983; [a]D20 in CH3OH =
+1.0 (c = 1.0).
4.4. (2S)-2-[(2S)-2-Amino-5-carbamimidamidopentanamido]-3-
(pyridin-3-yl)propanoic acid (4j)
Methyl (2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-5-{1-
[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]-
carbamimidamido}pentanamido]-3-(pyridin-3-yl)propanoate 2i
(170 mg; 0.25 mmol) and LiOH (15 mg; 0.62 mmol) were dissolved
in 2 mL of a THF/H2O 4:1 mixture, and allowed to react overnight
to yield 3j. Upon reaction completion, crude mixture was dissolved
in TFA, and general procedure for Boc and Pbf cleavage was fol-
lowed. Final product was a white solid (54 mg; 68%). 1H NMR
(D2O, 400 MHz) d 8.35 (s, 1H), 8.29–8.30 (d, J = 5.7 Hz, 1H), 8.16–
8.18 (d, J = 7.8 Hz, 1H), 7.61–7.65 (dd, J = 6.2, 8.3 Hz, 1H), 4.47–
4.51 (m, 1H), 3.65–3.68 t, J = 6.3 Hz, 1H), 3.10–3.15 (dd, J = 5.5,
14.7 Hz, 1H), 2.91–2.97 (dd, J = 8.8, 14.7 Hz, 1H), 2.78–2.81 (t,
J = 6.8 Hz, 2H), 1.49–1.54 (m, 2H), 1.19–1.28 (m, 2H); 13C NMR
(D2O, 100 MHz) d 172.5, 169.2, 156.3, 147.6, 140.9, 139.6, 137.0,
127.1, 52.5, 52.4, 40.1, 32.9, 27.7, 23.1; MS (ESI) m/z calculated
for [C12H20N6O+H+] = 323.2, found 323.1; [a]D20 in CH3OH = -18.0
(c = 1.0).
4.5. tert-Butyl-N-[(1S)-4-(carbamoylamino)-1-[(pyridine-4-
ylmethyl)carbamoyl]butyl]carbamate (8)
To a solution of L-Boc-Cit-OH 7 (750 mg; 2.72 mmol) in 15 mL of
DCM was added, in the stated order, HATU (1148 mg; 3.81 mmol),
TEA (1100 lL; 7.89 mmol) and 4-picolylamine (331 lL;
3.26 mmol). This mixture was stirred at r.t. for 5 h. Precipitate
formed was filtered, washed with DCM and dried under vacuum
to yield a white solid (776 mg; 78%). Rf 0.5 (DCM/MeOH 8:2); 1H
NMR (MeOD, 400 MHz) d 8.46–8.47 (d, J = 5.7 Hz, 2H), 7.38–7.39
(d, J = 5.7 Hz, 2H), 4.46–4.47 (m, 2H), 4.06–4.0 (m, 1H), 3.12–3.17
(q, J = 6.5 Hz, 2H), 1.77–1.84 (m, 1H), 1.52–1.69 (m, 3H), 1.47 (s,
9H); 13C NMR (MeOD, 100 MHz) d 174.4, 160.9, 156.6, 149.4,
148.6, 122.4, 79.3, 54.8, 41.4, 39.0, 29.0, 27.3, 26.5; MS (ESI), m/z
calculated for [C17N27N5O4+H+] = 366.2, found 366.2; [a]D20 in
MeOH = +5.0 (c = 1.0).
4.6. tert-Butyl N-[(1S)-4-(cyanoamino)-1-[(pyridine-4-
ylmethyl)carbamoyl]butyl]carbamate (9)
A solution of tert-butyl-N-[(1S)-4-(carbamoylamino)-1-[(pyri-
dine-4-ylmethyl)carbamoyl]butyl]carbamate 8 (358mg; 0.98mmol)
in 5 mL of pyridine was treated with CH3SO2Cl dropwise (152 lL;
1.96 mmol). Mixture was left to react at r.t. for 2 h. Pyridine was evap-
orated, and crude mixture purified by flash chromatography using a
DCM/MeOH 95:5 mixture as eluent, to afford a waxy yellow solid
(104 mg; 31%). Rf 0.5 (DCM/MeOH 9:1); 1H NMR (MeOD,
400 MHz) d 8.46–8.48 (m, 2H), 7.38–7.39 (d, J = 5.8 Hz, 2H), 4.47
(s, 2H), 4.08–4.10 (m, 1H), 3.05–3.08 (t, J = 6.8 Hz, 2H), 1.85–1.89
(m, 1H), 1.64–1.74 (m, 3H), 1.48 (s, 9H); 13C NMR (MeOD,
100 MHz) d 174.0, 156.6, 149.4, 148.6, 122.4, 117.2, 79.4, 54.6,44.8, 41.4, 28.6, 27.3, 26.1; MS (ESI), m/z calculated for [C17H25N5-
O3+H+] = 347.2, found 348.2; [a]D20 in MeOH = +4.0 (c = 1.0).
4.7. tert-Butyl N-[(1S)-4-(2-hydroxycarbamimidamido)-1-[(pyridine-
4-ylmethyl)carbamoyl]butyl]carbamate (10)
Precursor tert-butyl N-[(1S)-4-(cyanoamino)-1-[(pyridine-4-
ylmethyl)carbamoyl]butyl]carbamate 9 (98 mg; 0.31 mmol) was
dissolved in 1.5 mL of EtOH. To this solution, finely ground K2CO3
(85 mg; 0.61 mmol) and NH2OHHCl (43 mg; 0.61 mmol) were
added, and mixture stirred for 1 h at r.t. Solvent was evaporated,
and crude mixture purified by HPLC. Final product was a white
solid (89 mg; 83%). 1H NMR (MeOD, 400 MHz) d 8.78 (m, 2H),
7.99–8.00 (m, 2H), 4.69–4.70 (m, 2H), 4.08–4.12 (m, 1H), 3.25–
3.30 (t, J = 6.5 Hz, 2H), 1.85–1.90 (m, 1H), 1.71–1.78 (m, 3H), 1.48
(s, 9H); 13C NMR (MeOD, 100 MHz) d 174.6, 160.4, 159.1, 156.7,
141.5, 124.9, 79.6, 54.7, 42.1, 40.6, 28.4, 27.3, 25.1; MS (ESI), m/z
calculated for [C17H28N6O4+H+] = 381.2, found 381.2; [a]D20 in
MeOH = +6.0 (c = 1.0).
4.8. (2S)-2-Amino-5-(2-hydroxycarbamimidamido)-N-(pyridin-4-
ylmethyl)pentanamide (11a)
tert-Butyl N-[(1S)-4-(2-hydroxycarbamimidamido)-1-[(pyridin-
4-ylmethyl)carbamoyl]butyl]carbamate 10 (78 mg; 0.21 mmol)
was dissolved in 1 mL of a 1 M HCl solution and left to react over-
night. Solvent was freeze-dried, and a white solid was obtained
(70 mg; quant.). 1H NMR (MeOD, 400 MHz) d 8.85–8.86 (d,
J = 5.2 Hz, 2H), 8.09–8.11 (d, J = 5.3 Hz, 2H), 4.83 (m, under H2O sig-
nal, 1H), 4.70–4.75 (d, J = 17.3 Hz, 1 H), 4.14–4.19 (t, J = 5.8 Hz, 2H),
3.35–3.37 (m, under MeOD signal, 2H), 1.97–2.07 (m, 2H), 1.78–
1.80 (m, 2H); 13C NMR (MeOD, 100 MHz) d 169.4, 160.4, 159.0,
141.3, 125.5, 52.8, 42.3, 40.3, 28.3, 24.3; MS (ESI), m/z calculated
for [C14H21N5O3+H+] = 281.1648, found 281.1722; [a]D20 in
MeOH = +24.0 (c = 1.0).
4.9. Methyl 5-aminovalerate hydrochloride (13)
5-Aminovaleric acid 12 (2 g; 17.07 mmol) was dissolved in CH3-
OH (25 mL). The solution was cooled down to -10 C, and SOCl2
(2.84 mL; 39.06 mmol) was added dropwise onto the stirred solu-
tion. Mixture was warmed to room temperature and left to react
overnight. Solvent was evaporated under vacuum and the solid
residue triturated in Et2O. Final product was a white solid
(2.751 mg; 96%). Rf 0.7 (DCM/MeOH/NH4OH 85:14:1); 1H NMR
(MeOD, 400 MHz) d 3.69 (s, 3H), 2.96 (m, 2H), 2.41–2.45 (m, 2H),
1.70–1.74 (m, 4H); 13C NMR (MeOD, 100 MHz) d 173.9, 50.9,
39.1, 32.7, 26.5, 21.5; MS (ESI), m/z calculated for [C6H13NO2+H+]
= 132.1, found 132.1.
4.10. Methyl 5-[(tert-butoxicarbonyl)amino]valerate (14)
Methyl 5-aminovalerate 13 (1.575 g; 9.43 mmol) was sus-
pended in CH2Cl2 (20 mL). Boc2O (2.468 g; 11.31 mmol) and TEA
(1.577 mL; 11.31 mmol) were added successively, turning mixture
into a solution. Mixture was stirred at room temperature for 1.5 h.
Crude mixture was washed with HCl 0.5 N and brine, organic phase
dried over anhydrous Na2SO4, filtered and solvent evaporated
under vacuum. Crude residue was purified by flash chromatogra-
phy in Hex/EtOAc 7:3 as eluent. Final product was a colourless
thick oil (1.858 g; 85%). Rf 0.6 (Hex/EtOAc 1:1); 1H NMR (CDCl3,
400 MHz) d 3.67 (s, 3H), 3.10–3.15 (q, J = 6.8 Hz, 2H), 2.32–2.35
(t, J = 7.4 Hz, 2H), 1.62–1.69 (m, 2H), 1.49–1.55 (m, 2H), 1.44 (s,
9H); 13C (CDCl3, 100 MHz) d 173.9, 155.9, 79.1, 51.5, 40.1, 33.6,
29.5, 28.4, 22.0; MS (ESI), m/z calculated for [C11H21NO4 + Na+]
= 254.1, found 254.1.
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Methyl 5-[(tert-butoxicarbonyl)amino]valerate 14 (1.858 g;
8.04 mmol) was dissolved in 40 mL of a THF/H2O 4:1 mixture. LiOH
(231 mg; 9.65 mmol) was added to the solution. Mixture was
allowed to react overnight at room temperatureTHF was evapo-
rated under vacuum, H2O (8 mL) added to the resulting mixture
and acidified to pH = 1–2. Aqueous phase was extracted with
EtOAc (3  25 mL). Combined organic phases were washed with
brine, dried over anhydrous Na2SO4, filtered and solvent evapo-
rated under vacuum. Final product yielded a white solid (1.648 g;
94%). Rf 0.4 (Hex/EtOAc 1:1); 1H NMR (MeOD, 400 MHz) d 3.05–
3.08 (t, J = 6.9 Hz, 2H), 2.31–2.34 (t, J = 7.1 Hz, 2H), 1.60–1.67 (m,
2H), 1.50–1.55 (m, 2H), 1.45 (s, 9H); 13C NMR (MeOD, 100 MHz)
d 176.0, 157.1, 78.4, 39.5, 33.1, 29.0, 27.4, 21.8; MS (ESI),m/z calcu-
lated for [C10H19NO4 + Na+] = 240.1; found 240.1.
4.12. 5-[(N-Boc)amino]-N-(4-pyridinylmethyl)pentanamide (16)
5-[(tert-Butoxicarbonyl)amino]valeric acid 15 (499 mg;
2.30 mmol) was dissolved in 7.5 mL of DCM. HATU (1230 g;
3.22 mmol), TEA (930 lL; 6.67 mmol) and 4-picolylamine
(280 lL; 2.76 mmol) were added successively in the stated order.
Mixture was allowed to react at room temperature for 5 h. Crude
mixture was washed with sat. NaHCO3 and brine, dried over anhy-
drous Na2SO4, filtered and solvent evaporated under vacuum. Pro-
duct was purified by flash chromatography in a DCM/MeOH 96:4
mixture. Final product yielded a white solid (604 mg; 85%). Rf 0.5
(DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.42 (s, 2H), 7.09–
7.10 (d, J = 4.9 Hz, 2H), 6.89 (bs, 1H), 4.80 (bs, 1H), 4.33–4.34 (d,
J = 6.5 Hz, 2H), 3.01–3.06 (q, J = 6.2 Hz, 2H), 2.19–2.23 (t,
J = 7.5 Hz, 2H), 1.57–1.64 (p, J = 7.5 Hz, 2H), 1.39–1.46 (p,
J = 7.0 Hz, 2H), 1.33 (s, 9H); 13C NMR (CDCl3, 100 MHz) d 173.4,
156.3, 149.8, 147.9, 122.3, 79.2, 42.2, 39.6, 35.6, 29.5, 28.4, 22.7;
MS (ESI), m/z calculated for [C16H25N3O3+H+] = 308.4; found 308.3.
4.13. 5-(Carbamoylamino)-N-(4-pyridinylmethyl)pentanamide (17)
5-[(N-Boc)amino]-N-(4-pyridinylmethyl)pentanamide 16 (360mg;
1.17mmol) was dissolved in 1mL of methanol, to which 7mL of a
4 M solution of HCl in dioxane was added. Mixture was left to react
for 1.5 h at room temperature. Solvent was evaporated under vac-
uum. Crude mixture was cooled down to 0 C and treated with con-
centrated HCl (201 lL; 2.41 mmol). 2.5 mL of hot ethanol at 75 C
was added to the mixture. In a separated flask, KCNO (586 mg;
7.23 mmol) was dissolved in 2.5 mL of water, and this solution
added to the mixture containing the precursor, HCl and ethanol.
The resulting mixture was warmed to 70 C and left to react for
1 h. Ethanol was evaporated, the remaining aqueous phase was
basified to pH = 10 and freeze dried. The product was then taken
up in DCM, filtered and solvent evaporated under vacuum. Final
product was a pale solid (217 mg; 74%). Rf 0.5 (DCM/MeOH
84:16); 1H NMR (DMSO-d6, 400 MHz) d 8.51–8.52 (d, J = 6.2 Hz,
2H), 8.42–8.44 (bs, 1H), 7.25–7.27 (d, J = 5.8 Hz, 2H), 5.92–5.94
(bs, 1H), 5.38–5.42 (bs, 4H), 4.29–4.31 (d, J = 6.0 Hz, 2H),
2.94–2.99 (m, 2H), 2.17–2.21 (t, J = 7.3, 2H), 1.49–1.57 (m, 2H),
1.33–1.40 (m, 2H); 13C (DMSO-d6, 100 MHz) d 172.9, 160.0,
159.2, 149.7, 122.6, 41.5, 35.5, 30.2, 23.2; MS (ESI), m/z calcd for
[C12H18N4O2+H+] = 251.3, [C12H18N4O2 + Na+] = 273.3, [C12H18N4-
O2 + K+] = 289.3; found 251.2, 273.1, 289.1.
4.14. 5-(Cyanoamino)-N-(4-pyridinylmethyl)pentanamide (18)
5-(Carbamoylamino)-N-(4-pyridinylmethyl)pentanamide 17
(712 mg; 2.85 mmol) was suspended in 10 mL of pyridine. CH3SO2-
Cl (441 lL; 5.69 mmol) was added dropwise to mixture, and left toreact for 2 h at r.t.. Pyridine was evaporated, crude residue dis-
solved in commercial NH4OH and washed with DCM. Aqueous
phase was evaporated and product purified by flash chromatogra-
phy using DCM/MeOH 92:8 as eluent mixture. Final product was a
waxy yellow solid (330 mg; 50%). Rf 0.3 (DCM/MeOH 9:1); 1H NMR
(MeOD, 400 MHz) d 8.48–8.50 (m, 2H), 7.35–7.37 (m, 2H), 4.44 (s,
2H), 3.04–3.07 (t, J = 6.8 Hz, 2H), 2.33–2.37 (t, J = 7.0 Hz, 2H), 1.70–
1.79 (m, 2H), 1.60–1.68 (m, 2H); 13C NMR (MeOD, 100 MHz) d
174.5, 149.5, 148.7, 122.5, 117.3, 44.9, 41.5, 34.9, 29.0, 22.3; MS
(ESI) m/z calculated for [C12H16N4O+H+] = 232.1; found 232.1.
4.15. 5-(N00-Hydroxyguanidine)-N-(4-pyridinylmethyl)pentanamide
(11b)
5-(Cyanoamino)-N-(4-pyridinylmethyl)pentanamide 18 (325mg;
1.40 mmol) was dissolved in 6 mL of ethanol. NH2OHHCl (195mg;
2.80 mmol) and finely ground K2CO3 (387 mg; 2.80 mmol) were
added to the solution, and the mixture stirred for 1 h at r.t. Solvent
was evaporated, and crude purified by semipreparative HPLC. Final
product was a white solid (293 mg; 79%). 1H NMR (D2O, 400 MHz)
d 8.80–8.82 (m, 2H), 7.98–7.99 (m, 2H), 4.68 (s, 2H), 3.24–3.27 (t,
J = 7.0, 2H), 2.41–2.44 (t, J = 7.0, 2H), 1.62–1.77 (m, 4H); 13C (MeOD,
400 MHz) d 175.0, 161.1, 159.1, 141.2, 125.1, 42.2, 40.5, 34.6, 28.0,
22.2; MS (ESI), m/z calcd for [C12H18N4O2+H+] = 266.1539; found
266.1603.
4.16. (2S)-2-(Acetylamino)-5-(carbamoylamino)-N-(pyridin-4-
ylmethyl)pentanamide (19)
tert-Butyl-N-[(1S)-4-(carbamoylamino)-1-[(pyridine-4-ylmethyl)
carbamoyl]butyl]carbamate 8 (776mg; 2.12mmol) was dissolved in
15 mL of a mixture 2:1 dioxane/MeOH containing 2.66 M of HCl.
Mixture was left to react at r.t. for 1 h. Solvents were evaporated
under vacuum. Crude was dissolved in 12 mL of H2O and pH
adjusted to pH = 9–10 using an 8 M solution of NaOH. Mixture
was cooled to 0 C and Ac2O (401 lL; 4.24 mmol) was added drop-
wise. pH was adjusted again to 9–10, and mixture left to react at
r.t. for 3 h. Water was evaporated, and crude residue purified by
flash chromatography using DCM/MeOH 82:18 as eluent. Final pro-
duct was a white solid (386 mg; 59%). Rf 0.2 (DCM/MeOH 82:18); 1H
NMR (MeOD, 400MHz) d 8.47–8.48 (m, 2H), 7.37–7.38 (d, J = 5.6 Hz,
2H), 4.48–4.52 (d, J = 16.5 Hz, 1H), 4.40–4.44 (d, J = 16.5 Hz,
1H),4.34–4.37 (dd, J = 8.8 Hz, 5.4 Hz, 1H), 3.10–3.21 (m, 2H), 2.03
(s, 3H), 1.82–1.90 (m, 1H), 1.51–1.76 (m, 3H); 13C NMR (MeOD,
100MHz) d 173.6, 172.3, 160.9, 149.6, 148.5, 122.4, 53.6, 41.5,
38.9, 28.8, 26.5, 21.0; MS (ESI), m/z calculated for [C14H21N5O3+H+]
= 308.2, found 308.1; [a]D20 in MeOH = +3.0 (c = 1.0).
4.17. (2S)-5-(Cyanoamino)-2-acetamido-N-(pyridin-4-ylmethyl)
pentanamide (20)
(2S)-2-(Acetylamino)-5-(carbamoylamino)-N-(pyridin-4-ylmethyl)
pentanamide 19 (60 mg; 0.20 mmol) was dissolved in 1 mL of
pyridine and warmed up to 40 C in order to facilitate dilution.
CH3SO2Cl (30 lL; 0.39 mmol) was added dropwise, and mixture
left to react at 40 C for 2 h. Pyridine was evaporated and crude
residue purified by flash chromatography using a mixture of
DCM/MeOH 92:8 as eluent. Final product was a yellow oil
(21 mg; 36%). Rf 0.6(DCM/MeOH 85:15); 1H NMR (MeOD,
400 MHz) d 8.49–8.48 (m, 2H), 7.39–7.38 (m, 2H), 4.53–4.48 (d,
J = 16.3 Hz, 1H), 4.45–4.41 (d, J = 16.3 Hz, 1H), 4.39–4.36 (m, 1H),
3.08–3.05 (t, J = 6.7 Hz, 2H), 2.04 (s, 3H), 1.95–1.88 (m, 1H), 1.79–
1.63 (m, 3H); 13C (MeOD, 100 MHz) d 173.2, 172.2, 149.5, 148.6,
122.4, 117.2, 53.3, 44.7, 41.5, 28.4, 26.0, 21.0; MS (ESI), m/z calcu-
lated for [C14H19N5O2+H+] = 290.1, found 290.1; [a]D20 in MeOH =
+5.0 (c = 1.0).
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4-ylmethyl)pentanamide (11c)
(2S)-5-(Cyanoamino)-2-acetamido-N-(pyridine-4-ylmethyl)
pentanamide 20 (21 mg; 0.07 mmol) was dissolved in 0.5 mL of
EtOH. NH2OHHCl (10 mg; 0.14 mmol) and TEA (10 lL; 0.07 mmol)
were added to the solution and mixture stirred for 1 h at r.t. Sol-
vent was evaporated and mixture purified by HPLC. Final product
was a white solid (17 mg; 75%). 1H NMR (MeOD, 400 MHz) d
8.80 (m, 2H), 8.02–8.01 (m, 2H), 4.76–4.72 (d, J = 17.7 Hz, 1H),
4.67–4.63 (d, J = 17.7 Hz, 1H), 4.35–4.32 (dd, J = 8.0 Hz, 5.2 Hz,
1H), 3.29–3.26 (t, J = 7.0 Hz, 3H), 2.06 (s, 3H), 1.97–1.88 (m, 1H),
1.83–1.65 (m, 3H); 13C NMR (MeOD, 100 MHz) d 173.8, 172.7,
161.0, 159.1, 141.1, 125.0, 53.7, 42.1, 40.3, 28.1, 25.1, 21.0; MS
(ESI), m/z calculated for [C14H22N6O3+H+] = 323.1753,
found = 323.1806; [a]D20 in MeOH = +4.0 (c = 1.0).
4.19. (2S)-2-Amino-5-(carbamoylamino)-N-(pyridin-4-ylmethyl)
pentanamide (21a)
tert-Butyl-N-[(1S)-4-(carbamoylamino)-1-[(pyridine-4-ylmethyl)-
carbamoyl]butyl]carbamate 8 (271mg; 0.74 mmol) was dissolved in
2 mL of TFA. Mixture was left to react at r.t. for 1 h. Solvent was evap-
orated under vacuum, and product triturated in Et2O. Final product
yielded a white solid (278 mg; quant.). 1H NMR (D2O, 400 MHz) d
8.65–8.66 (m, 2H), 7.87–7.88 (m, 2H), 4.67 (s, 2H), 4.07–4.10 (t,
J = 6.31 Hz, 1H), 3.05–3.08 (t, J = 6.8 Hz, 2H), 1.84–1.92 (m, 2H),
1.45–1.52 (m, 2H); 13C NMR (D2O,100 MHz) d 170.4, 162.1–163.2
(q, J = 33.6 Hz, TFA), 161.3, 159.4, 141.0, 125.2, 111.8–120.5 (q,
J = 290.2 Hz, TFA), 52.9, 42.5, 38.9, 28.1, 24.7; MS (ESI)m/z calculated
for [C12H19N5O2+H+] = 266.1539, found 266.1608; [a]D20 in H2O =
+10.0 (c = 1.0).
4.20. tert-Butyl N-[(1S)-4-(carbamoylamino)-1-[(pyridine-3-
ylmethyl)carbamoyl]butyl]carbamate (22)
To a solution of the amino acid Boc-L-Cit-OH 7 (250 mg;
0.91 mmol) in DCM (5 mL) was added, in the stated order, HATU
(483 mg; 1.27 mmol), TEA (368 lL; 2.64 mmol) and 3-picoly-
lamine (111 lL; 1.09 mmol). This mixture was stirred at r.t. for
5 h. Solvent was evaporated, and the remaining residue was puri-
fied by flash chromatography using a DCM/MeOH 9:1 mixture as
solvent. Final product was obtained as white solid (276 mg; 83%).
Rf 0.25 (DCM/MeOH 9:1); 1H NMR (CDCl3, 400 MHz) d 8.41–4.86
(m, 2H), 7.55–7.57 (m, 1H), 7.51 (bs, 1H), 7.16–7.18 (m, 1H),
5.42–5.43 (bs, 1H), 5.13 (bs, 1H), 4.53 (bs, 1H), 4.42–4.47 (dd,
J = 15.1, 6.2 Hz, 1H), 4.28–4.33 (dd, J = 15.5, 5.8 Hz, 1H), 4.24 (bs,
1H),3.30–3.31 (m, 1H), 3.01–3.06 (m, 2H), 1.69–1.76 (m, 1H),
1.39–1.58 (m, 3H), 1.34 (s, 9H); 13C NMR (CDCl3, 100 MHz) d
173.2, 160.2, 156.1, 148.6, 148.2, 135.6, 134.4, 123.6, 79.8, 54.0,
40.7, 39.2, 30.0, 28.3, 26.5; MS (ESI) m/z calculated for [C17H27N5-
O4+H+] = 366.4, found 366.5; [a]D20 in CHCl3 = -4.0 (c = 1.0)
4.21. (2S)-2-Amino-5-(carbamoylamino)-N-(pyridin-3-ylmethyl)
pentanamide (21b)
tert-Butyl N-[(1S)-4-(carbamoylamino)-1-[(pyridine-3-ylmethyl)-
carbamoyl]butyl]carbamate 22 (270 mg; 0.74 mmol) was dissolved
in 2mL of TFA. Mixture was left to react at r.t. for 1 h. Solvent was
evaporated under vacuum, and product triturated in Et2O. Final pro-
duct yielded a white solid (261mg; 93%). 1H NMR (D2O, 400 MHz) d
8.64–8.67 (m, 2H), 8.45–8.47 (m, 1H), 7.97–8.00 (dd, J = 7.9, 6.0 Hz,
1H), 4.57 (s, 2H), 3.98–4.01 (t, J = 6.6 Hz, 2H), 3.00–3.04 (t,
J = 6.7 Hz), 1.79–1.85 (m, 2H), 1.38–1.45 (m, 2H), 13C NMR (D2O,
100 MHz) d 170.1, 162.1–163.2 (q, J = 36.5 Hz, TFA), 161.3, 146.0,
140.2, 139.9, 138.3, 127.4, 111.8–120.5 (q, J = 284.6 Hz, TFA), 52.8,40.0, 38.9, 28.0, 24.7; MS (ESI) m/z calculated for [C12H19N5O2+H+]
= 266.1539, found 266.1612; [a]D20 in H2O = +13.0 (c = 1.0).
4.22. N-[(1S)-4-(Carbamoylamino)-1-[(pyridin-4-yl)carbamoyl]
butyl]carbamate (23)
To a solution of the amino acid Boc-L-Cit-OH 7 (150 mg;
0.54 mmol) in DCM (2.5 mL) was added, in the stated order, HATU
(290 mg; 0.76 mmol), TEA (218 lL; 1.57 mmol) and 4-aminopy-
ridine (61 mg; 0.65 mmol). This mixture was stirred at r.t. for
5 h. Solvent was evaporated, and the remaining residue was puri-
fied by flash chromatography using a DCM/MeOH 88:12 mixture
as solvent. Final product was obtained as white solid (140 mg;
74%). Rf 0.4 (DCM/MeOH 85:15); 1H NMR (MeOD, 400 MHz) d
8.40–8.41 (m, 2H), 7.69–7.70 (m, 2H), 4.24–4.27 (m, 1H), 3.21–
3.27 (m, 1H), 3.08–3.15 (m, 1H), 1.82–1.85 (m, 1H), 1.56–1.74
(m, 3H), 1.46 (bs, 9H); 13C NMR (MeOD, 100 MHz) d 173.2, 161.0,
156.7, 149.3, 146.6, 113.8, 79.3, 55.0, 38.7, 29.1, 27.3, 26.5; MS
(ESI) m/z calculated for [C16H25N5O4+H+] = 352.4, found 352.5;
[a]D20 in CHCl3 = -5.0 (c = 1.0).
4.23. (2S)-2-Amino-5-(carbamoylamino)-N-(pyridin-4-yl)
pentanamide (21c)
N-[(1S)-4-(Carbamoylamino)-1-[(pyridine-4-yl)carbamoyl]butyl]-
carbamate 23 (125 mg; 0.36 mmol) was dissolved in 2.5 mL of a mix-
ture 2:1 dioxane/methanol containing 2.66M of HCl. Mixture was
left to react at r.t. for 1 h. Solvents were evaporated under vacuum.
Final product was yielded as a white solid (102 mg; quant.). 1H
NMR (D2O, 400 MHz) d 8.49–8.50 (d, J = 6.9 Hz, 2H), 8.01–8.03 (d,
J = 6.9 Hz, 2H), 4.21–4.24 (m, 1H), 3.01–3.05 (t, J = 6.6 Hz, 2H),
1.88–1.98 (m, 2H), 1.50–1.53 (m, 2H); 13C NMR (D2O, 100 MHz) d
169.8, 161.2, 152.4, 141.9, 115.8, 54.0, 38.9, 27.7, 24.4; MS (ESI) m/
z calculated for [C11H17N5O2+H+] = 252.1382, found 252.1454; [a]D20
in H2O = +16.0 (c = 1.0).
4.24. Hyperpolarisation and NMR experiments
para-hydrogen was produced by cooling H2 gas over a spin-
exchange catalyst (Fe2O3) at 30 K temperature. This method was
able to provide para-hydrogen with more than 93% purity. Samples
involved in the analysis were prepared with  6 mg of ligand
(60 lM) and 2 mg of IMes precursor catalyst (3 lM) dissolved
in 0.6 ml deuterated methanol solvent in a 5 mm NMR tube fitted
with a J. Young’s tap. The resulting solutions were then degassed
by 3 cycles of freeze-pumpthaw method before filling the tube
with pH2 at a pressure of 3 bar. Once filled with pH2, the tubes
were shaken vigorously for 10 s in a fringe field of 65 Gauss
around a 9.4 T Bruker spectrometer or Earth’s magnetic field.
Immediately after that, tubes were rapidly transported inside the
spectrometer for subsequent NMR detections. Enhancement factor
was calculated by taking the ratio of the integrals of peaks in the
hyperpolarised spectra and thermal equilibrium spectra. Catalyst
precursor was synthesised in our laboratory according to a litera-
ture procedure1 [IMes = 1,3-bis(2,4,6-trimethylphenyl) imidazole-
2-ylidene and COD = cis,cis-1,5-cyclooctadiene]. T1 measurement
experiments were performed using 8 mg of compound in the form
of HCl salt (same amount used in the SABRE hyperpolarisation
experiments) dissolved in 0.6 mL of PBS buffer pH = 7.4 and 37 C.
4.25. Enzymatic tests
eNOS (bovine recombinant) was purchased from Cayman
chemicals and used as received. 1 U of enzyme produced 1 nM/
min of NO at 37 C in 50 mM HEPES buffer (pH 7.4) with 1 mM
CaCl2, 20 mg/ml CaM, 0.1 mM NADPH, 50 mM L-arginine and
2742 F. Fernandez Diaz-Rullo et al. / Bioorganic & Medicinal Chemistry 25 (2017) 2730–274212 mM tetrahydrobiopterin. The amount of enzyme in 1 U was cal-
culated from the batch specific activity as shown on the data sheet.
L-Arginine analogues 4a–i and 12a–c were tested using 1 U of
enzyme in the stated conditions against an L-arginine positive con-
trol and a negative control solution in a total reaction volume of
100 lL. The reaction was optimised to 40 min. 3 lL of an ice-cold
solution containing 20 mM HEPES (pH 5.5), 2 mM EDTA and
2 mM EGTA were added to stop the reaction. The concentration
of NO was determined using the colorimetric Griess reaction by
following the nitrate/nitrite colorimetric assay kit LDH method
provided by Cayman chemicals.
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